Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
In a phased rollout, the jabs eventually will be offered to those with a BMI of 35 or more and weight-related health problems ...
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...
Ozempic and other diabetes-weight loss drugs have been linked to at least 162 deaths and 10,000 cases involving “serious” ...
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
NHS says a quarter of a million people will be offered tirzepatide - brand name Mounjaro - after trials showed it helped obese participants lose a fifth of their body weight ...